Skip to content
Therapy But Better – Lifestyle
Author:
Nuvation Bio, Inc.
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo
April 1, 2026
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 26, 2026
←
Previous Page
1
2
3